Ultrasound-Guided Suprazygomatic Maxillary Nerve Block as A Part of Multimodal Analgesic Regimens

The Effect of Ultrasound-Guided Suprazygomatic Maxillary Nerve Block for Minimize the Post-operative Pain in Tonsillectomy Surgery

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05023239

Enrollment

Registered

2021-08-26

Start date

2021-10-01

Completion date

2022-12-01

Last updated

2021-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suprazygomatic Maxillary Nerve Block

Brief summary

Inadequate peri-operative analgesia may contribute to an increased risk of bleeding, suture dehiscence and unacceptable surgical outcomes. Moreover, these patients are at high risk of postoperative airway obstruction and respiratory failure. Opioids may contribute to these complications. Appropriate use of regional anaesthesia may mitigate or eliminate many of these concerns. The maxillary nerve is responsible for the sensory innervation of the midface, including the hard and soft palates, upper jaw, upper dental arch and upper lip.Recently, the successful use of maxillary nerve block by the suprazygomatic approach has been reported in children undergoing cleft palate surgery. However, the use of this block has not been described in large series of patients, and the effectiveness of the suprazygomatic approach has not been evaluated in patients undergoing tonsillectomy .

Interventions

OTHERUG-SZM Group

The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

4 Years to 12 Years

Healthy volunteers

Inclusion criteria

* Inclusion criteria 1. Pediatric patients aged 4-12 years 2. Genders eligible for study: both sexes 3. ASA physical status I and II 4. Undergoing tonsillectomy surgery

Exclusion criteria

* Parents' refusal * Contraindications to regional anesthesia * Known allergy to local anesthetics * Bleeding disorders * Children with diabetes mellitus, obstructive sleep apnea syndrome, cardiac, renal, liver or blood diseases, swallowing disorders or peritonsillar abscess, * Children receiving regular analgesia within the last week before surgery, * Children undergoing simultaneous procedure in the field of surgery like adenoidectomy or tongue tie will be all excluded from the study.

Design outcomes

Primary

Measure	Time frame	Description
postoperative Meperidine consumption	24 hours	total dose of Meperidine consumption

Secondary

Measure	Time frame	Description
incidence of complication	24 hours	postoperative complication

Contacts

Primary Contactamr wahdan, MD

amr_amw010@hotmail.com01001422499

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026